Difference between revisions of "Pyrotinib (Irene)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pyrotinib NCI Drug Dictionary]: An orally bioavailable, dual...") |
m (→Also known as) |
||
(2 intermediate revisions by the same user not shown) | |||
Line 8: | Line 8: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
− | * | + | * 2018-08-22: Initial conditional authorization |
==Also known as== | ==Also known as== | ||
+ | *'''Code name:''' SHR-1258 | ||
*'''Brand name:''' Irene | *'''Brand name:''' Irene | ||
Line 21: | Line 22: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
− | [[Category:NMPA approved | + | [[Category:NMPA approved in 2018]] |
Latest revision as of 13:02, 8 September 2023
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells.
Route: PO
Extravasation: n/a
Diseases for which it is used
History of changes in NMPA indication
- 2018-08-22: Initial conditional authorization
Also known as
- Code name: SHR-1258
- Brand name: Irene